Identification of neuroprotective properties of anti-MAG antibody: a novel approach for the treatment of stroke?

被引：37

作者：

Irving, EA ^{[1
]}

Vinson, M ^{[1
]}

Rosin, C ^{[1
]}

Roberts, JC ^{[1
]}

Chapman, DM ^{[1
]}

Facci, L ^{[1
]}

Virley, DJ ^{[1
]}

Skaper, SD ^{[1
]}

Burbidge, SA ^{[1
]}

Walsh, FS ^{[1
]}

Hunter, AJ ^{[1
]}

Parsons, AA ^{[1
]}

机构：

[1] GlaxoSmithKline Res & Dev Ltd, Neurol & GI CEDD, Harlow CM19 5AW, Essex, England

来源：

JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM | 2005年 / 25卷 / 01期

关键词：

CNS recovery; middle cerebral artery occlusion; monoclonal antibody; myelin-associated glycoprotein; neuroprotection; oligodendrocyte;

D O I：

10.1038/sj.jcbfm.9600011

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The inhibitory activity of myelin-associated glycoprotein (MAG) on neurons is thought to contribute to the lack of regenerative capacity of the CNS after injury. The interaction of MAG and its neuronal receptors mediates bidirectional signaling between neurons and oligodendrocytes. The novel finding that an anti-MAG monoclonal antibody not only possesses the ability to neutralise the inhibitory effect of MAG on neurons but also directly protects oligodendrocytes from glutamatemediated oxidative stress-induced cell death is reported here. Furthermore, administration of antiMAG antibody (centrally and systemically) starting 1 hour after middle cerebral artery occlusion in the rat significantly reduced lesion volume at 7 days. This neuroprotection was associated with a robust improvement in motor function compared with animals receiving control IgG1. Together, these data highlight the potential for the use of anti-MAG antibodies as therapeutic agents for the treatment of stroke.

引用

页码：98 / 107

页数：10

共 54 条

[1]

Back SA, 1998, J NEUROSCI, V18, P6241

[2] Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease [J].

Bard, F ;

Cannon, C ;

Barbour, R ;

Burke, RL ;

Games, D ;

Grajeda, H ;

Guido, T ;

Hu, K ;

Huang, JP ;

Johnson-Wood, K ;

Khan, K ;

Kholodenko, D ;

Lee, M ;

Lieberburg, I ;

Motter, R ;

Nguyen, M ;

Soriano, F ;

Vasquez, N ;

Weiss, K ;

Welch, B ;

Seubert, P ;

Schenk, D ;

Yednock, T .

NATURE MEDICINE, 2000, 6 (08) :916-919

[3]

Brösamle C, 2000, J NEUROSCI, V20, P8061

[4] The problem of assessing effective neuroprotection in experimental cerebral ischemia [J].

Corbett, D ;

Nurse, S .

PROGRESS IN NEUROBIOLOGY, 1998, 54 (05) :531-548

[5] Calcium-permeable AMPA/kainate receptors mediate toxicity and preconditioning deprivation in by oxygen-glucose oligodendrocyte precursors [J].

Deng, WB ;

Rosenberg, PA ;

Volpe, JJ ;

Jensen, FE .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (11) :6801-6806

[6] Oligodendrocytes as providers of growth factors [J].

Du, YZ ;

Dreyfus, CF .

JOURNAL OF NEUROSCIENCE RESEARCH, 2002, 68 (06) :647-654

[7] Axonal damage in acute multiple sclerosis lesions [J].

Ferguson, B ;

Matyszak, MK ;

Esiri, MM ;

Perry, VH .

BRAIN, 1997, 120 :393-399

[8] Neuroscience - New insights into neuron-glia communication [J].

Fields, RD ;

Stevens-Graham, B .

SCIENCE, 2002, 298 (5593) :556-562

[9] Functional assessments in mice and rats after focal stroke [J].

Hunter, AJ ;

Hatcher, J ;

Virley, D ;

Nelson, P ;

Irving, E ;

Hadingham, SJ ;

Parsons, AA .

NEUROPHARMACOLOGY, 2000, 39 (05) :806-816

[10] To what extent have functional studies of ischaemia in animals been useful in the assessment of potential neuroprotective agents? [J].

Hunter, AJ ;

Mackay, KB ;

Rogers, DC .

TRENDS IN PHARMACOLOGICAL SCIENCES, 1998, 19 (02) :59-66

← 1 2 3 4 5 6 →